Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Income from Continuing Operations (2017 - 2025)

Arcus Biosciences has reported Income from Continuing Operations over the past 9 years, most recently at 106000000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 106000000.0 for Q4 2025, down 12.77% from a year ago — trailing twelve months through Dec 2025 was 353000000.0 (down 24.73% YoY), and the annual figure for FY2025 was 353000000.0, down 24.73%.
  • Income from Continuing Operations for Q4 2025 was 106000000.0 at Arcus Biosciences, up from 135000000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for RCUS hit a ceiling of 279538000.0 in Q4 2021 and a floor of 135000000.0 in Q3 2025.
  • Median Income from Continuing Operations over the past 5 years was 75970000.0 (2021), compared with a mean of 60894736.84.
  • Peak annual rise in Income from Continuing Operations hit 637.62% in 2021, while the deepest fall reached 4379.64% in 2021.
  • Arcus Biosciences' Income from Continuing Operations stood at 279538000.0 in 2021, then tumbled by 123.97% to 67000000.0 in 2022, then fell by 20.9% to 81000000.0 in 2023, then dropped by 16.05% to 94000000.0 in 2024, then fell by 12.77% to 106000000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 106000000.0 (Q4 2025), 135000000.0 (Q3 2025), and 112000000.0 (Q1 2025) per Business Quant data.